At least three members of the FDA panel deciding whether BPC-157, TB-500, and five other peptides get a legal compounding pathway have financial ties to the peptide industry — including two who currently sell peptides to patients. The Associated Press reported the conflicts on June 29, 2026, less than a month before the panel's July 23-24 vote.
The story, carried by PBS NewsHour, ABC News, NBC News, and dozens of other outlets, lands in the middle of an already tense review: FDA's own career scientists released briefing documents on June 30 recommending against all seven peptides, while HHS Secretary Robert F. Kennedy Jr. has publicly pushed to widen access.
Research-context information only. BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon are research peptides sold for research purposes only. The details below come from AP reporting and public FDA records. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
Who the AP identified
Reporter Matthew Perrone's AP story names three panelists with direct financial stakes in the peptide market:
- Dr. Haleem Mohammed runs Florida clinics under the Gameday Men's Health chain that sell injections of peptides, vitamins, testosterone, and weight-loss medications. He told AP the compounded medications his clinics offer "are not FDA-approved."
- Dr. Gabriel Alizaidy charges $500 for "peptide and hormone" consultations and promotes BPC-157, GHK-Cu, and other peptides to a large following on Instagram and TikTok. He described his content as "educational in nature" and said it "does not constitute medical care."
- Bobby Harshbarger, a Tennessee state senator, is a pharmacist at his family's business, Premiere Pharmacy, which sells compounded weight-loss, longevity, and pain peptides. His mother, U.S. Rep. Diana Harshbarger, previously wrote to Kennedy urging him to relax FDA restrictions on several peptides.
AP reported the reshaped panel includes "more than a half-dozen" members with some form of industry connection — the three named above are the ones with the clearest financial stake in the substances under review. Neither the FDA nor HHS has issued a public response to the specific ties as of this writing.
Update: how the July 23-24 vote played out
The committee met July 23-24 and recommended six of the seven peptides for the 503A Bulks List, rejecting only one. The tallies, as reported by STAT, The Hill, Fierce Pharma and others (FDA's official transcript posts later, typically about 30 days after the meeting):
| Peptide | Recommendation | Vote |
|---|---|---|
| BPC-157 | Recommended | 8-6 (1 abstention) |
| KPV | Recommended | 8-6 (1 abstention) |
| TB-500 | Recommended | 8-6 (1 abstention) |
| MOTS-c | Recommended | 7-5 (2 abstentions) |
| Semax | Recommended | 8-5 |
| Epitalon | Recommended | 7-4 |
| Emideltide (DSIP) | Rejected | 6-7 |
The conflict-of-interest question this article flagged did shape the pattern — though not in the way "rigged" implies. Reporting from NBC News and STAT described the yes votes as coming substantially from the temporary voting members HHS added days before the meeting — six of the eight of whom sell or administer peptides — with several voting together on the day-one substances. The no votes came from the committee's evidence-and-safety members, on the record with their reasons: MD Anderson anesthesiologist and medication-safety specialist Elizabeth Rebello cited the "lack of efficacy data and randomized controlled trials"; USC transplant hepatologist Brian Lee warned an FDA sign-off could be read as an endorsement of unproven products; patient advocate Josh Mailman and others said the efficacy evidence was too thin. These were documented, substance-specific objections about evidence and safety — not pharmaceutical-industry ones.
Two things did not change. The votes are advisory and non-binding — the FDA makes the final call, and its own career scientists had recommended against all seven in their June 30 briefing. And even the six favorable recommendations only start a formal rulemaking process that realistically extends into 2027 before any pharmacy could act on it. Full per-peptide breakdown and what each outcome means for access: FDA Panel Backs 6 Peptides for Compounding, Rejects DSIP.
Why this lands now — and why it matters for buyers
The timing sharpens an existing fight. On June 30, FDA career scientists released briefing documents recommending that none of the seven peptides be added to the 503A Bulk Drug Substances List, citing thin human safety and efficacy data — we covered that staff recommendation here. NPR separately reported that same week on internal tension between FDA scientists and Kennedy's push to expand access.
A panel stacked with members who profit from continued (or expanded) peptide sales complicates that picture in a specific way: it does not tell you which direction the vote goes. Industry-tied panelists could vote to approve compounding (expanding their own legal footing) or, just as plausibly, decline to draw regulatory attention to businesses that currently operate in a gray zone. What the story establishes is a credibility problem with the process, not a predicted outcome.
For anyone sourcing these peptides today, the practical calculus is unchanged either way:
- A "yes" vote on any of the seven only starts formal FDA rulemaking — a process that realistically extends into 2027 before any pharmacy could act on it.
- A "no" vote simply keeps things exactly where they are: all seven peptides already came off Category 2 in April 2026, and research-use-only sourcing remains fully available regardless of the committee's decision.
Nothing about the panel composition story changes pricing, stock, or where these peptides can be bought this week.
Where to source the peptides under review
Every peptide in this review is available through research-use-only vendors today, unaffected by the panel controversy or the underlying vote. Compare live cost-per-mg, COA verification, and current coupons below.
